[1] |
Chen Shuangshuang, Tian Lili, Wang Nenhan, Yang Xinyu, Zhao Yanfeng, Li Chuanyou, Dai Xiaowei.
Analysis of in vitro antibacterial effects of 17 antibiotics against rapidly growing mycobacteria in the Beijing area
[J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1056-1062.
|
[2] |
Li Yang, Sun Feng, Zhang Wenhong.
Short-course treatment for tuberculosis: past achievements and future directions
[J]. Chinese Journal of Antituberculosis, 2024, 46(9): 991-997.
|
[3] |
Yu Lan, Chen Shuangshuang, Wang Nenhan, Tian Lili, Zhao Yanfeng, Fan Ruifang, Liu Haican, Li Chuanyou, Dai Xiaowei.
Consistency between phenotypic resistance to fluoroquinolones and genetic mutations in rifampicin resistant Mycobacterium tuberculosis strains
[J]. Chinese Journal of Antituberculosis, 2024, 46(8): 942-950.
|
[4] |
Cheng Mengli, Jiang Guanglu, Huo Fengmin, Xue Yi, Yu Xia.
Evaluation of in vitro activity of fusidic acid against mycobacteria
[J]. Chinese Journal of Antituberculosis, 2024, 46(4): 461-466.
|
[5] |
Pei Shaojun, Ou Xichao.
Interpretation of the World Health Organization’s Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance (2nd Edition)
[J]. Chinese Journal of Antituberculosis, 2024, 46(3): 260-266.
|
[6] |
Wang Xueyu, Shi Wenhui, Li Qi, Jing Wei, Chu Naihui, Nie Wenjuan.
Efficacy and safety of Baidiziyin Pill and Shenqiyifei Pill in adjuvant treatment of susceptible pulmonary tuberculosis patients: a national randomized controlled multicenter clinical study
[J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1306-1312.
|
[7] |
Ge Jing, Wang Jun, He Yuqi, Nie Wenjuan.
Six cases of pseudomembranous colitis caused by anti-tuberculosis drugs and literature review
[J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1320-1326.
|
[8] |
Li Xuelian, Jing Wei, Wang Qingfeng, Chu Naihui, Nie Wenjuan.
An all-oral shortened regimen containing new drugs to treat MDR/rifampicin-resistant tuberculosis: three case reports and literature review
[J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1327-1334.
|
[9] |
Li Jing, Jiang Qi, Jiang Yuan, Shen Xin.
Evaluation of performance of PCR fluorescent probe method for detecting Mycobacterium tuberculosis complex and rifampicin resistance
[J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1250-1258.
|
[10] |
Fu Liang, Deng Guofang.
MDR-Chin study analysis: prospects of using all-oral short-course treatment regimens for multidrug-resistant pulmonary tuberculosis in China
[J]. Chinese Journal of Antituberculosis, 2024, 46(1): 18-22.
|
[11] |
Song Yuanyuan, Xia Hui, Zhao Yanlin.
Development process of setting of critical concentrations for phenotypic drug susceptibility testing of Mycobacterium tuberculosis
[J]. Chinese Journal of Antituberculosis, 2023, 45(7): 631-638.
|
[12] |
Fu Liang, Ren Tantan, Zhang Peize, Lu Shuihua.
Interpretation of WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update
[J]. Chinese Journal of Antituberculosis, 2023, 45(4): 336-348.
|
[13] |
Zhu Yumei, Xia Zihan, Li Jinli, He Huishan, Wang Feng.
Application value of multicolor melting curve analysis in detection of pre-extensive drug-resistant pulmonary tuberculosis
[J]. Chinese Journal of Antituberculosis, 2023, 45(4): 406-411.
|
[14] |
Zhou Feng, Li Tongxin, Yang Song, Tang Shenjie.
Progress on short-course regimens for the treatment of tuberculosis
[J]. Chinese Journal of Antituberculosis, 2023, 45(3): 311-317.
|
[15] |
Ge Qiping, Zhang Lijie, Huang Xuerui, Jiang Guanglu, Han Xiqin, Wang Jingping, Du Jian, Ma Yan, Gao Weiwei.
Effect of a new treatment regimen on patients with initially retreated drug-sensitive pulmonary tuberculosis
[J]. Chinese Journal of Antituberculosis, 2023, 45(11): 1078-1083.
|